Sublingual misoprostol as an adjunct to oxytocin during cesarean delivery in women at risk of postpartum hemorrhage

What Was Tested

The paper reports a study of Oxytocin, published as a randomized controlled trial.

Who Took Part

The age groups tagged for this paper are young adults and adults, women only.

Women were eligible if they were undergoing emergency cesarean under spinal anesthesia and were at high risk for PPH.

Participants and providers were masked to assignment.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Oxytocin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Oxytocin study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Oxytocin, giving a reference point.

A prospective, randomized, double-blind, placebo-controlled trial was performed at a tertiary care center in Kolkata, India, between October 2012 and December 2013.

The primary outcomes were intraoperative and postoperative blood loss.

What Was Measured

PubMed files the paper under topics including Abortifacient Agents, Nonsteroidal, Administration, Sublingual, Blood Loss, Surgical, Blood Volume, Cesarean Section, Emergencies and Fever.

Author keywords: Cesarean delivery, Misoprostol, Postpartum hemorrhage and Risk factors.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Oxytocin.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2015 (International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics), a journal based in United States.

More context: the Oxytocin compound page, all human trials.